Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non-Current Assets for 9 consecutive years, with -$234.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Non-Current Assets changed N/A to -$234.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was -$224.6 million, a N/A change, with the full-year FY2024 number at $106.8 million, down 13.53% from a year prior.
  • Non-Current Assets was -$234.7 million for Q2 2025 at Akebia Therapeutics, down from -$203.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $280.8 million in Q2 2021 to a low of -$234.7 million in Q2 2025.
  • A 5-year average of $139.3 million and a median of $165.5 million in 2022 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 4.55% in 2021; the steepest drop was 41.0% in 2021.
  • Akebia Therapeutics' Non-Current Assets stood at $258.2 million in 2021, then plummeted by 33.82% to $170.9 million in 2022, then decreased by 27.69% to $123.6 million in 2023, then dropped by 13.53% to $106.8 million in 2024, then plummeted by 319.64% to -$234.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Assets are -$234.7 million (Q2 2025), -$203.8 million (Q1 2025), and $106.8 million (Q4 2024).